Versican in nonsmall cell lung cancer: relation to hyaluronan, clinicopathologic factors, and prognosis.
The aim of the study was to investigate the expression and prognostic role of versican in 212 patients with resected nonsmall cell lung cancer. Tumor samples were stained immunohistochemically, and the versican staining was evaluated both in tumor stroma and cancer cells. The staining results were compared to the clinical data of the patients, the tumor cell proliferation, and the expression of hyaluronan. In the whole material, low and high area percentages of stromal versican staining were observed in 135 and 77 carcinomas, respectively. Tumor cell-associated staining signal for versican was observed in 33 cases. In the whole material, the significant relationship between high stromal staining of versican and that of hyaluronan was noticed (P = .001). The expression of stromal versican was related to tumor type (P = .008) and high stromal staining was inversely correlated with poor tumor differentiation (P = .045), but not with tumor cell proliferation. Among adenocarcinomas, the high stromal staining of versican was associated with tumor recurrence (P = .024), higher tumor stage (P = .022), and lymph node metastases (P = .042). Versican expression was not related to patient outcome in the whole material, but among adenocarcinomas, the high stromal staining was related to poor disease-free survival (P = .0056). However, in Cox multivariate analysis with tumor stage, versican expression did not retain its prognostic significance. The results indicate that increased stromal versican is related to higher tumor recurrence rate and more advanced disease. Despite the important role of versican in nonsmall cell lung cancer, traditional clinicopathologic factors remained most significant in the current study.
Pirinen
Risto
R
Department of Pathology and Forensic Medicine, University of Kuopio and Kuopio Univeristy Hospital, Finland.
Leinonen
Tero
T
Böhm
Jan
J
Johansson
Risto
R
Ropponen
Kirsi
K
Kumpulainen
Eero
E
Kosma
Veli-Matti
VM
D000328:Adult; D014408:Biomarkers, Tumor / Q000032:analysis*; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D011508:Chondroitin Sulfate Proteoglycans / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000096:biosynthesis*; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D008207:Lymphatic Metastasis / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D009419:Nerve Tissue Proteins / Q000096:biosynthesis*; D011379:Prognosis; D053675:Versicans
D014408:Biomarkers, Tumor; D011508:Chondroitin Sulfate Proteoglycans; D009419:Nerve Tissue Proteins; C508322:VCAN protein, human; D053675:Versicans; D006820:Hyaluronic Acid